PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18065490-5	2007	Flavopiridol suppressed c-FLIP-l/s and BCL-xL expression, whereas vorinostat reduced expression of BCL-xL, and combined exposure to flavopiridol and vorinostat reduced MCL-1 and X-chromosome-linked inhibitor of apoptosis protein (XIAP) levels.	alvocidib	0-12	BCL2 like 1	Homo sapiens	39-45	
22693249-6	2012	Mechanistic investigations revealed that flavopiridol inhibited Mcl-1 transcription but increased transcription of Bim and its binding to Bcl-2/Bcl-xL.	alvocidib	41-53	BCL2 like 1	Homo sapiens	144-150	
18065490-5	2007	Flavopiridol suppressed c-FLIP-l/s and BCL-xL expression, whereas vorinostat reduced expression of BCL-xL, and combined exposure to flavopiridol and vorinostat reduced MCL-1 and X-chromosome-linked inhibitor of apoptosis protein (XIAP) levels.	alvocidib	132-144	BCL2 like 1	Homo sapiens	39-45	
18065490-9	2007	Flavopiridol suppressed extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT activity and expression of activated forms of AKT and mitogen-activated protein/ERK kinase 1 maintained c-FLIP-l/s, BCL-xL, and XIAP expression and protected cells against flavopiridol/vorinostat lethality.	alvocidib	0-12	BCL2 like 1	Homo sapiens	199-205	
18065490-10	2007	Overexpression of c-FLIP-s and BCL-xL abolished the lethality of flavopiridol/vorinostat.	alvocidib	65-77	BCL2 like 1	Homo sapiens	31-37	
16820931-10	2006	In summary, flavopiridol augmented TRAIL sensitivity by up-regulation of TRAIL receptors and down-regulation of survivin, FLIP and Bcl-xL.	alvocidib	12-24	BCL2 like 1	Homo sapiens	131-137	
16219908-2	2006	Coadministration of flavopiridol with HDAC inhibitors synergistically potentiated mitochondrial damage (cytochrome c, second mitochondria-derived activator of caspases/direct IAP binding protein with low pI, and apoptosis-inducing factor release), caspase activation, poly(ADP-ribose) polymerase degradation, and cell death in both wild type and Bcl-2- or Bcl-x(L)-overexpressing cells and induced a pronounced loss of clonogenicity.	alvocidib	20-32	BCL2 like 1	Homo sapiens	356-361	
12457721-0	2003	Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells.	alvocidib	0-12	BCL2 like 1	Homo sapiens	89-94	
15039284-4	2004	In imatinib mesylate-resistant K562 cells displaying increased Bcr/Abl expression, bortezomib/flavopiridol treatment markedly increased apoptosis in association with down-regulation of Bcr/Abl and BclxL, and diminished phosphorylation of Lyn, Hck, CrkL, and Akt.	alvocidib	94-106	BCL2 like 1	Homo sapiens	197-202	
15634644-4	2004	Combined exposure to flavopiridol and HA14-1 was associated with down-regulation of Mcl-1 and Bcl-xL, Bid cleavage, and mitochondrial translocation of Bax.	alvocidib	21-33	BCL2 like 1	Homo sapiens	94-100	
12457721-5	2003	While Bcl-2 and Bax expression did not change, Bcl-x(L) was down regulated and Bcl-xs was up-regulated after being exposed to flavopiridol.	alvocidib	126-138	BCL2 like 1	Homo sapiens	47-55	
12457721-9	2003	Flavopiridol not only inhibits CDKs directly, but it also inhibits the CDKs activation pathway and activates the Bcl-x apoptotic pathway.	alvocidib	0-12	BCL2 like 1	Homo sapiens	113-118	
12231544-5	2002	STI571/flavopiridol-mediated apoptosis was associated with the caspase-independent down-regulation of Bcl-x(L) and Mcl-1, activation of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase, and the caspase-dependent release of Smac/DIABLO and loss of deltapsi(m).	alvocidib	7-19	BCL2 like 1	Homo sapiens	102-110	
24990615-0	2014	Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.	alvocidib	97-106	BCL2 like 1	Homo sapiens	74-80